Yusuke Inoue, Asuka Oda, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, Tomoko Maruhashi, Mamiko Takahashi, Shiro Fujii, Shingen Nakamura, et al. Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid. International journal of hematology. 2024
Kimiko Sogabe, Shingen Nakamura, Yoshiki Higa, Hirokazu Miki, Asuka Oda, Tomoko Maruhashi, Ryohei Sumitani, Masahiro Oura, Mamiko Takahashi, Masafumi Nakamura, et al. Acute accumulation of PIM2 and NRF2 and recovery of β5 subunit activity mitigate multiple myeloma cell susceptibility to proteasome inhibitors. International journal of hematology. 2024. 119. 3. 303-315
Targeting myeloma metabolisms regulated by HDAC1-IRF4 axis can be a novel therapeutic strategy
(17th International Myeloma Workshop 2019)
Peri-implantitis and the role of Febuxostat in osteoclast differentiation.
(AEEDC Dubai World Orthodontic Conference 2019)
The critical role of the HDAC1-IRF4-Pim-2 axis in myeloma cell growth and survival: therapeutic impacts of targeting the HDAC1-IRF4-Pim-2 axis
(60th ASH Annual Meeting & Exposition 2018)
Alteration of muscle mass after chemotherapy in patients with newly diagnosed multiple myeloma.
(Esmo asia 2018 2018)
Roles of HDAC1 and HDAC3 as therapeutic targets against myeloma cells
(The 80th Annual Meeting of the Japanese Society of Hematology 2018)
2013/12/07 - American Society of Hematology ASH Abstract Achievement Award Robust induction of Th1-like gamma delta T cells with anti-myeloma activity by lenalidomide in combination with HMB-PP as well as zoledronic acid